✦ LIBER ✦

Solitary minute hepatocellular carcinoma. A study of 14 patients

✍ Scribed by Xin-Da Zhou; Zhao-You Tang; Ye-Qin Yu; Zeng-Chen Ma; Bing-Hui Yang; Ji-Zhen Lu; Zhi-Ying Lin; Jie Wang

Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 345 KB
Volume: 67
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19910601)67:11<2855::aid-cncr2820671125>3.0.co;2-a

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II study of irinotecan in patien

A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma

✍ Eileen M. O'Reilly; Keith E. Stuart; Pedro M. Sanz-Altamira; Gary K. Schwartz; C 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB 👁 2 views

Phase II study of thalidomide in patient

Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma

✍ Albert Y. Lin; Nathalie Brophy; George A. Fisher; Sam So; Christopher Biggs; Tor 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

Phase II study of gemcitabine in patient

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma

✍ Tai-Shen Yang; Yung-Chang Lin; Jen-Shi Chen; Hung-Ming Wang; Chen-Hsu Wang 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 2 views

Phase 2 study of cetuximab in patients w

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

✍ Andrew X. Zhu; Keith Stuart; Lawrence S. Blaszkowsky; Alona Muzikansky; Donald P 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB

## Abstract ## BACKGROUND. Epidermal growth factor receptor (EGFR) and ligand expression is frequently seen in hepatocellular carcinoma (HCC). A phase 2 study was performed with cetuximab, a chimeric monoclonal antibody that binds specifically to EGFR, in patients with advanced HCC. ## METHODS.

Phase 2 study of erlotinib in patients w

Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

✍ Melanie B. Thomas; Romil Chadha; Katrina Glover; Xuemei Wang; Jeffrey Morris; Th 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 1 views

## Abstract ## BACKGROUND. Growth factor overexpression, including epidermal growth factor receptor (EGFR) expression, is common in hepatocellular cancers. Erlotinib is a receptor tyrosine kinase inhibitor with specificity for EGFR. The primary objective of this study was to determine the proporti

Hepatocellular carcinoma in noncirrhotic

Hepatocellular carcinoma in noncirrhotic patients. A laparoscopic study of 92 cases in Taiwan

✍ D. Y. Lin; Yun-Fan Liaw; C. M. Chu; C. S. Chang-Chien; C. S. Wu; P. C. Chen; I. 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 272 KB 👁 3 views

Clinical and laboratory findings of 92 cases of pathologically verified noncirrhotic primary hepatocellular carcinoma (HCC) were analyzed and compared with that of 174 cases of cirrhotic HCC during the same period. Ninety-two cases of noncirrhotic HCC constitute one third of all the cases of HCC. Th